Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | 2C28H45N3O7.C10H18O4 |
| Molecular Weight | 1273.5931 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 10 / 10 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)CCCCCCCCC(O)=O.CC(C)C1=C(CC2=CC=C(OCCCNCC(C)(C)C)C=C2C)C(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)=NN1.CC(C)C4=C(CC5=CC=C(OCCCNCC(C)(C)C)C=C5C)C(O[C@@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O)=NN4
InChI
InChIKey=CSBVKUZBZNEFOB-TVESCGIASA-N
InChI=1S/2C28H45N3O7.C10H18O4/c2*1-16(2)22-20(26(31-30-22)38-27-25(35)24(34)23(33)21(14-32)37-27)13-18-8-9-19(12-17(18)3)36-11-7-10-29-15-28(4,5)6;11-9(12)7-5-3-1-2-4-6-8-10(13)14/h2*8-9,12,16,21,23-25,27,29,32-35H,7,10-11,13-15H2,1-6H3,(H,30,31);1-8H2,(H,11,12)(H,13,14)/t2*21-,23-,24+,25-,27+;/m11./s1
GSK-1614235 (mizagliflozin) is a sodium glucose co-transporter type 1 (SGLT1) inhibitor that has been investigated for treatment in type 2 diabetes. It is thought to suppress glucose absorption from the intestine in a way that is different from conventional type 2 diabetes drugs, thereby improving postprandial hyperglycemia. Phase 1 studies have been completed.
Originator
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
76959210
Created by
admin on Fri Dec 15 19:38:23 GMT 2023 , Edited by admin on Fri Dec 15 19:38:23 GMT 2023
|
PRIMARY | |||
|
2N0WP693VN
Created by
admin on Fri Dec 15 19:38:23 GMT 2023 , Edited by admin on Fri Dec 15 19:38:23 GMT 2023
|
PRIMARY |
